Inclusion Criteria:
- ELIGIBILITY CRITERIA FOR ENROLLMENT INTO STEPS 1, 2, AND 3
- Patients must have germline or somatic mutations in DDR genes: ARID1A, ATM, ATRX,
BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2,
PARP1, POLD1, PP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, XRCC2; or actionable mutations
in the PTEN gene, or hotspot mutations in the PIK3CA gene (E542, E545 or H1047 are
accepted). Local testing in Clinical Laboratory Improvement Act (CLIA)-certified
laboratory will be accepted. Only mutations that have been recognized as actionable by
the MD Anderson Precision Oncology Decision Support (PODS) team will be accepted
- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or
are no longer effective
- Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1
- Patients must be >= 4 weeks beyond treatment with any chemotherapy or other
investigational therapy to include hormonal, biological, or targeted agents; or at
least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter
at the time of treatment initiation
- Patients with a mutation within both the DDR and PTEN/PIK3CA pathways will be assessed
by the genomics Precision Oncology Decision Support group at MD Anderson, and the
patient will be allocated to the PI3K or DDR expansion group deemed to be the main
driver. If the actionability between the groups is deemed to be equivocal, then the
patient will be allocated to the expansion cohort with fewer patients
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 1 (Karnofsky >=
60%)
- Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days
- Leukocytes >= 3,000/mcL
- Lipase =< 1.5 x upper limit of normal (ULN)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 x institutional ULN
- Serum bilirubin =< 1.5 x institutional ULN
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 x institutional ULN, unless liver metastases are present in which case they
must be =< 5 x ULN
- Activated partial thrombin time =< 1.5 x ULN unless subject is receiving anticoagulant
therapy as long as prothrombin time (PT) or partial thromboplastin time (PTT) is
within the therapeutic range of intended use of anticoagulants
- International normalized ratio =< 1.5 x ULN
- Glomerular filtration rate (GFR) >= 51 mL/min, based on a 24-hour urine test for
creatinine clearance or estimated using the Cockcroft-Gault equation
- Left ventricular ejection fraction (LVEF) >= 50%
- Patients who are therapeutically treated with an agent such as warfarin or heparin
will be allowed to participate provided that their medication dose and international
normalized ratio (INR)/PTT is stable
- Prophylactic antiemetics may be administered according to standard practice. The
routine use of standard antiemetics, including 5-hydroxytryptamine type 3 (5-HT3)
blockers, such as granisetron, ondansetron, or an equivalent agent, is allowed as
needed. The use of corticosteroids as antiemetics prior to copanlisib administration
will not be allowed
- Postmenopausal or evidence of non-childbearing status, a negative urine or serum
pregnancy test within 28 days of study treatment and confirmed prior to treatment on
day 1. Postmenopausal is defined as:
- Amenorrheic for 1 year or more following cessation of exogenous hormonal
treatments
- Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the
postmenopausal range for women under 50
- Radiation-induced oophorectomy with last menses > 1 year ago
- Chemotherapy-induced menopause with > 1 year interval since last menses
- Surgical sterilization (bilateral oophorectomy or hysterectomy)
- Women of child-bearing potential MUST have a negative serum or urine human chorionic
gonadotropin (HCG) test unless prior tubal ligation (>= 1 year before screening),
total hysterectomy or menopause (defined as 12 consecutive months of amenorrhea).
Patients should not become pregnant or breastfeed while on this study
- Patients and their partners, if sexually active and of childbearing potential, must
agree to the use of two highly effective forms of contraception in combination
throughout the period of taking study treatment and for 6 months after last dose of
study drug(s) to prevent pregnancy in the study patient or partner. Male patients
should avoid donating sperm for 3 months following the last dose of olaparib
- Human immunodeficiency virus (HIV)-infected (HIV 1/2 antibody-positive; HIV testing
pre-study not required) patients may participate IF they meet all the following
eligibility requirements:
- They must be on an anti-retroviral regimen with evidence of at least two
undetectable viral loads within the past 6 months on this same regimen; the most
recent undetectable viral load must be within the past 12 weeks
- They must have a CD4 count >= 250 cells/mcL over the past 6 months on this same
anti-retroviral regimen and must not have had a CD4 count < 200 cells/ mcL over
the past 2 years, unless it was deemed related to the cancer and/or
chemotherapy-induced bone marrow suppression
- For patients who have received chemotherapy in the past 6 months, a CD4
count < 250 cells/mcL during chemotherapy is permitted as long as viral
loads were undetectable during this same chemotherapy
- They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within
7 days of enrollment
- They must not be currently receiving prophylactic therapy for an opportunistic
infection and must not have had an opportunistic infection within the past 6
months
- Glycosylated hemoglobin (HbA1C) of =< 8.5% at screening
- Ability to understand and the willingness to sign a written informed consent document.
Patients with impaired decision-making capacity (IDMC) must have a legally authorized
representative or caregiver who gives such consent
- Patient is willing and able to comply with the protocol for the duration of the study,
including undergoing treatment and scheduled visits and examinations
- Patients with a tumor that is readily accessible for biopsy
- ELIGIBILITY CRITERIA FOR ENROLLMENT INTO STEP 2 AND 3 ONLY
- Body weight > 30 kg
- Life expectancy >= 16 weeks
Exclusion Criteria:
- EXCLUSION CRITERIA FOR STEPS 1, 2, AND 3
- Patients who are receiving any other investigational agents
- Other malignancy unless curatively treated with no evidence of disease for >= 5 years
except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer
of the cervix, ductal carcinoma in situ (DCIS), or stage 1, grade 1 endometrial
carcinoma. A patient with a history of localized triple negative breast cancer may be
eligible, provided the patient completed the adjuvant chemotherapy > 3 years prior to
registration, and the patient remains free of recurrent or metastatic disease
- Patients with myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or with bone
marrow findings consistent with MDS/AML
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to olaparib, copanlisib, PI3K inhibitors or MEDI4736 (durvalumab) or any
of the excipients of any study products
- Concomitant use of strong CYP3A inhibitors and inducers
- Olaparib: concomitant use of known strong CYP3A inhibitors (e.g., itraconazole,
telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or
cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or
moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin, diltiazem,
fluconazole, verapamil). The required washout period for strong or moderate CYP3A
inhibitors prior to starting olaparib is 2 weeks
- Because the lists of these agents are constantly changing, it is important to
regularly consult a frequently-updated medical reference. As part of the
enrollment/informed consent procedures, the patient will be counseled on the risk
of interactions with other agents, and what to do if new medications need to be
prescribed or if the patient is considering a new over-the-counter medicine or
herbal product
- Concomitant use of known strong CYP3A inducers (e.g., phenobarbital,
enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine,
nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan,
efavirenz, modafinil). The required washout period for strong or moderate CYP3A
inducers prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital
and 3 weeks for other agents
- Copanlisib: copanlisib is primarily metabolized by CYP3A4. Therefore, the
concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,
clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and strong
inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St.
John's Wort) are not permitted from 14 days prior to enrollment until the end of
the study
- Other medications that are prohibited while on copanlisib treatment:
- Herbal medications/preparations (except for vitamins)
- Anti-arrhythmic therapy other than beta blockers or digoxin
- Because the lists of these agents are constantly changing, it is important to
regularly consult a frequently-updated medical reference for a list of drugs to
avoid or minimize use of. As part of the enrollment/informed consent procedures,
the patient will be counseled on the risk of interactions with other agents, and
what to do if new medications need to be prescribed or if the patient is
considering a new over-the-counter medicine or herbal product
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, uncontrolled major seizure disorder, unstable spinal cord compression,
superior vena cava syndrome, extensive interstitial bilateral lung disease on high
resolution computed tomography (HRCT) scan, symptomatic congestive heart failure,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements
- Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible
cardiac conditions, as judged by the investigator (e.g., unstable ischemia,
uncontrolled symptomatic arrhythmia, congestive heart failure, QT corrected by the
Fridericia formula [QTcF] prolongation of > 500 msec, electrolyte disturbances), or
patients with congenital long QT syndrome
- Women who are breast feeding or pregnant are excluded from this study because olaparib
is a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with olaparib, breastfeeding should be discontinued if the mother is treated
with olaparib and copanlisib +/- MEDI4736 (durvalumab)
- Previous allogenic bone marrow transplant or double umbilical cord blood
transplantation (dUCBT)
- Packed red blood cell or platelet transfusion in the last 28 days prior to study entry
- Whole blood transfusions in the last 120 days prior to study entry. Whole blood
transfusions performed within 120 days of study entry may interfere with blood samples
taken for exploratory analysis
- Patients should be excluded if they have a condition requiring systemic treatment with
either corticosteroids (> 10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drug administration. However,
systemic corticosteroids may be indicated after starting the study drugs to treat
immune-related adverse reactions. Inhaled or topical steroids and adrenal replacement
doses =< 10 mg daily prednisone equivalents are permitted in the absence of active
autoimmune disease
- Patients with non-healing wound, ulcer, or bone fracture
- Patients with HbA1c > 8.5%
- Note: for patients with newly diagnosed diabetes mellitus that cannot meet
protocol requirements, a single re-screening (which includes all screening
procedures) should be performed when then patient's diabetes is controlled and
can meet protocol eligibility requirement for HbA1c
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident
(including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
within 6 months before the start of study medication
- Patients with active, clinically serious infections > grade 2 (Common Terminology
Criteria for Adverse Events [CTCAE] version [v] 5.0). Active infection including
tuberculosis (clinical evaluation that includes clinical history, physical examination
and radiographic findings, and tuberculosis [TB] testing in line with local practice),
hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result),
or hepatitis C. Patients with a past or resolved HBV infection (defined as the
presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.
Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain
reaction is negative for HCV ribonucleic acid (RNA). HBV/HCV screening is required 28
days prior to starting the study drug using a routine hepatitis virus lab panel
- Active infection requiring IV antibiotics or other uncontrolled intercurrent illness
requiring hospitalization
- Patients unable to swallow orally administered medication and any medical condition or
diagnosis that would likely impair absorption of an orally administered drug (e.g.
gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)
- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Subjects with previously treated brain metastases may participate provided they are
stable (without evidence of progression by imaging for at least four weeks prior to
the first dose of trial treatment and any neurologic symptoms have returned to
baseline), have no evidence of new or enlarging brain metastases, and are not using
steroids for at least 7 days prior to trial treatment. This exception does not include
carcinomatous meningitis which is excluded regardless of clinical stability
- New York Heart Association class III or IV heart disease
- History or concurrent interstitial lung disease of any severity and/or severely
impaired lung function (as judged by the investigator)
- Uncontrolled arterial hypertension despite optimal medical management (per
investigator's opinion)
- EXCLUSION STEPS 2 AND 3 ONLY
- Patients who have not re
